Evidence map›Paper›PMID 24278482›Full record

ArticlePloS one2013

Decorin mimic inhibits vascular smooth muscle proliferation and migration.

Rebecca A Scott, John E Paderi, Michael Sturek, Alyssa Panitch

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Biomimetic strategies for the deputization of proteoglycan functions.Frontiers in cell and developmental biology · 2024
    Review
  3. Article
  4. Proteoglycans and proteoglycan mimetics for tissue engineering.American journal of physiology. Cell physiology · 2022
    Review
  5. Article
  6. Article
  7. A Possible Role for Arylsulfatase G in Dermatan Sulfate Metabolism.International journal of molecular sciences · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rebecca A ScottWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, United States of America.
John E Paderi
Michael Sturek
Alyssa Panitch
Purdue University West Lafayette · USIndiana University School of Medicine

Funding

Improved Therapeutics for Drug Eluting StentsR01HL106792 · NHLBI · PURDUE UNIVERSITY · PI PANITCH, ALYSSA · 2011 to 2014
$1.5M
NHLBI NIH HHS NIH R01HL106792NHLBI NIH HHS R01 HL106792
6 · The paper itself

Abstract

Over the past 10 years, the number of percutaneous coronary intervention procedures performed in the United States increased by 33%; however, restenosis, which inhibits complete functional recovery of the vessel wall, complicates this procedure. A wide range of anti-restenotic therapeutics have been developed, although many elicit non-specific effects that compromise vessel healing. Drawing inspiration from biologically-relevant molecules, our lab developed a mimic of the natural proteoglycan decorin, termed DS-SILY, which can mask exposed collagen and thereby effectively decrease platelet activation, thus contributing to suppression of vascular intimal hyperplasia. Here, we characterize the effects of DS-SILY on both proliferative and quiescent human SMCs to evaluate the potential impact of DS-SILY-SMC interaction on restenosis, and further characterize in vivo platelet interactions. DS-SILY decreased proliferative SMC proliferation and pro-inflammatory cytokine secretion in vitro in a concentration dependent manner as compared to untreated controls. The addition of DS-SILY to in vitro SMC cultures decreased SMC migration and protein synthesis by 95% and 37%, respectively. Furthermore, DS-SILY decreased platelet activation, as well as reduced neointimal hyperplasia by 60%, in vivo using Ossabaw swine. These results indicate that DS-SILY demonstrates multiple biological activities that may all synergistically contribute to an improved treatment paradigm for balloon angioplasty.

Indexed as

Cell MovementCell ProliferationMolecular MimicryCells, CulturedDecorinHumansMuscle, Smooth, VascularPlatelet ActivationThrombomodulinTunica IntimaDCN protein, humanDecorinThrombomodulin

Identifiers

PMID24278482
PMCPMC3838406
OpenAlexW2036110029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.